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STUDY DESIGN: Clinical trial.
OBJECTIVE: To demonstrate that a 12-week exoskeleton-based robotic gait training regimen can lead to a clinically meaningful
improvement in independent gait speed, in community-dwelling participants with chronic incomplete spinal cord injury (iSCI).
SETTING: Outpatient rehabilitation or research institute.
METHODS: Multi-site (United States), randomized, controlled trial, comparing exoskeleton gait training (12 weeks, 36 sessions) with
standard gait training or no gait training (2:2:1 randomization) in chronic iSCI (>1 year post injury, AIS-C, and D), with residual
stepping ability. The primary outcome measure was change in robot-independent gait speed (10-meter walk test, 10MWT) post 12week intervention. Secondary outcomes included: Timed-Up-and-Go (TUG), 6-min walk test (6MWT), Walking Index for Spinal Cord
Injury (WISCI-II) (assistance and devices), and treating therapist NASA-Task Load Index.
RESULTS: Twenty-ﬁve participants completed the assessments and training as assigned (9 Ekso, 10 Active Control, 6 Passive
Control). Mean change in gait speed at the primary endpoint was not statistically signiﬁcant. The proportion of participants with
improvement in clinical ambulation category from home to community speed post-intervention was greatest in the Ekso group
(>1/2 Ekso, 1/3 Active Control, 0 Passive Control, p < 0.05). Improvements in secondary outcome measures were not signiﬁcant.
CONCLUSIONS: Twelve weeks of exoskeleton robotic training in chronic SCI participants with independent stepping ability at
baseline can improve clinical ambulatory status. Improvements in raw gait speed were not statistically signiﬁcant at the group level,
which may guide future trials for participant inclusion criteria. While generally safe and tolerable, larger gains in ambulation might
be associated with higher risk for non-serious adverse events.
Spinal Cord; https://doi.org/10.1038/s41393-022-00751-8

INTRODUCTION
In the chronic phase after incomplete spinal cord injury (iSCI), those
individuals with residual gait function, may improve walking
function by engaging in an intensive gait training regimen [1–3].
Rehabilitation robotic exoskeletons can readily deliver a participantspeciﬁc and precise high-dose training regimen, and may simultaneously reduce the physical stress imposed on therapists, relative to
conventional gait training strategies, such as manually assisted
stepping practice via harness and treadmill. Exoskeleton training is
predicted to improve walking function in participants receiving
usual care, but not expected to be superior to intensity-matched
manual training, or other labor-intensive gait training strategies. The
rationale to implement exoskeleton robotics as a preference in gait

training is based on precision dosing, overground (OG) training, and
reduced therapist burden for high-repetition training. We consider
that robotic exoskeleton gait training in SCI is cost effective [4], not
to replace the skilled human operator and clinical decision-maker,
but rather to offset the heavy manual labor requirement that
continues to be a substantial and under-reported occupational risk
for therapists [5–7].
Furthermore, clinical research related to OG robotic exoskeletons has been mostly limited to safety and tolerability trials or
single-arm clinical studies [8–11], or randomized trials assessing
device-dependent gait function [12]. There are currently no
randomized controlled clinical trials comparing the impact of
robotic exoskeleton OG training vs. conventional gait training
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strategies on independent gait function in individuals with
chronic iSCI.
The primary objective of the present study was to demonstrate
that an OG robotic exoskeleton-based 12-week gait training
regimen, can lead to a clinically meaningful improvement in
robot-independent walking speed.
METHOD
Study design
This was a randomized, prospective, multi-center, assessor-blind, longitudinal, comparative study to evaluate the efﬁcacy of robotic exoskeleton
gait training versus standard gait training or usual care. The practice
schedule followed a prior robotic rehabilitation clinical trial [13], while the
treatment session structure and progression were developed by the
investigators.
Prior to the randomization phase, each site was required to enroll one to
three participants in a run-in phase. The run-in phase was designed to (1)
train and carefully supervise the sites prior to starting the randomization
(2) test the recruiting ability of the selected sites (3) test the assessment
time-points for primary and secondary endpoints, and (4) ensure that the
inclusion/exclusion criteria were adequate. As the run-in phase was
intended for study-speciﬁc training and participants were not randomized,
these data were not included for analysis.
Participants could volunteer for the study if they had motor incomplete
upper motor neuron paraplegia or tetraplegia, from traumatic or nontraumatic injury at least one year prior, and self-selected gait speed of
<0.44 meters/second (m/s) with the ability to take at least one step (see
Table 1 for full list of inclusion and exclusion criteria). Study participants
were recruited from outpatient clinics and advertisement to local spinal
cord injury organizations, following Institutional Review Board (IRB)
approval at each site. Informed consent was obtained for all participants.

Intervention
Run-in participants. One to three participants per site were required to
complete the Ekso intervention protocol as run-in participants, to ensure
that assessment and training procedures were practiced and followed as
required in the clinical trial protocol.
Following the satisfactory completion of at least one set of midpoint
assessments during the run-in phase, subsequent main study participants
(a separate cohort) were enrolled and randomly assigned to one of three
study arms via a computer-generated allocation table. These study arms
included Ekso Robotic Intervention, Active Control or Passive Control (2:2:1
randomization ratio, respectively).
Ekso intervention. Ekso GT robotic gait training (3x/wk, 12 weeks,
36 sessions) sessions comprised 45 min of gait training in the Ekso
device (minimum 300 steps per session, Fig. 1), and if possible, OG
training without body weight support (BWS). The 45 min excluded setup/donning/dofﬁng time and included standing/up time, walking time,
and seated rest breaks. Standard OG gait training was introduced when
the participant required only minimal assistance of one therapist and one
aide to help control the assistive device. This was assessed weekly during
the 10-meter walk test (10MWT) performed every 3rd session. At that
point, sessions consisted of 30 min of session time gait training in the
Ekso, followed by 15 min of session time performing standard OG gait
training outside the Ekso, for a total of 45 min. See Table 2A for the Ekso
training timing, settings and progression strategy. In brief, the 15-min OG
gait training could take place at the ﬁrst session if the criterion for
assistance was met. During the 15-min OG gait training, any intervention,
device, or bracing could be used (except Ekso, Body Weight Supported
Treadmill Training, BWSTT, or any BWS). Stairs could be included during
this OG gait training for a maximum of 5 min per session when the
participant was able to perform them with only minimal assist or less of
one physical therapist (PT).
Active Control. The practice schedule was matched for the Active
Control group, with each session comprising 45 min of BWSTT, and if
possible, OG training without BWS. The 45 min excluded set-up/
harnessing time and included standing time, walking time, and seated
rest breaks. Sessions began with a minimum of 300 steps during BWSTT.
Commencement criteria of OG training matched the Ekso group, and
once achieved: (1) If the initial 300 steps were not completed by the end

of the ﬁrst segment, the middle 15-min segment was required to be gait
training in BWSTT, and the ﬁnal 15-min segment was required to be OG
gait training, (2) If the initial 300 steps were completed by the end of the
ﬁrst segment, the middle 15-min segment could be continued gait
training in BWSTT or OG gait training, per PT choice. The ﬁnal 15-min
segment was required to be OG gait training. See Table 2B for the BWSTT
training progression strategy. The OG gait training took place at the ﬁrst
session if the criterion for assistance was met. During OG gait training,
the same rules applied in this group as for the Ekso group. The Active
Control training protocol was based on standard clinical practice
guidelines at participating sites, with emphasis on task-speciﬁc training
focusing on intensity and dose.
Passive Control. Participants in this group continued with daily activities
as normal over 12 weeks. No new gait training, mobility therapy, nor new
medications related to the condition under study, were to be commenced
during the study period. Participants in this group came to the study sites
for evaluations at baseline, 6 and 12 weeks. Participants randomized to this
Passive Control group were offered Ekso Active or Active BWSTT sessions
at the conclusion of their 12-week participation.

Outcome measures
Demographic and other outcome measures were evaluated by blinded
ASIA Impairment Scale (AIS) trained physical therapists. The primary
endpoint of this study was change in gait speed (m/s) demonstrated
during the 10MWT after the 12-week intervention (36 sessions), relative to
baseline. Additional assessments were performed at the intervention
period midpoint (6 weeks), and 12 weeks post-intervention for the active
intervention groups. Both self-selected and fast speeds were performed.
For each, the average of two trials was used for analysis. The number of
participants who achieved the Minimal Clinically Important Difference
(MCID) of 0.15 m/s [14] and the number of participants who transitioned
from exercise or household ambulation (deﬁned as self-selected walking
speed of ≤0.44 m/s) to limited community or full community ambulation
(>0.44 m/s) [15] during the self-selected speed gait assessment were also
reported.
Secondary outcome measures included the Timed Up and Go (TUG) for
functional mobility and balance (seconds), the 6-min walking test for
endurance (meters), and the WISCI-II score (0–20 scale) for need of
assistance and devices.
A dedicated Adverse Event (AE) and Serious Adverse Event (SAE) set of
forms was used to track safety outcomes. Throughout the training period,
an independent Data and Safety Monitoring Board (DSMB) assessed and
adjudicated all SAEs and protocol violations. An independent study
monitor reviewed trial and data quality at each site, during the run-in and
ﬁnal trial phase.
For comparison of therapist manual burden between active interventions, we employed the NASA-Task Load Index (TLX). The TLX is a widely
used, validated measure of self-reported workload [16]. The instrument
assesses perceived mental, physical, and temporal demands as well as
effort, performance and frustration associated with a job task. Each
dimension is rated on a visual analog scale (VAS) ranging from 0 to 20. The
VAS is anchored using the terms ‘low’ and ‘high’.

Sample size determination
The present study terminated early for reasons independent of trial
ﬁndings as there was no interim analysis before stopping, rather the
ﬁnancial capability of the sponsor led to cessation of trial funding during
the third year, and thus our results are unlikely to introduce bias by
stopping [17]. Our analyses took place with the available data.

Statistical analyses
This study design involved outcome variables measured on binomial and
polynomial as well as continuous scales. For the continuous outcome
variables, the general situation applied analysis of variance and covariance
when there were g distinct groups with a sample of observations for each
group. The general null hypothesis was that the outcome variable
distribution was the same for the Ekso Group and the Active Control
Group. The assumptions associated with the analysis of variance were: (1)
the g samples were independent random samples, (2) the observations in
group i (for each i = 1,2,…,g) were a random sample from a normal
probability distribution with mean μi and variance σi2, and (3) the g
population variances, σ12,….,σg2, were equal to a common variance σ2.

Spinal Cord
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Table 1.

WISE trial inclusion and exclusion criteria.

Inclusion criteria

Exclusion criteria

1. Motor incomplete paraplegia or tetraplegia, chronic (> 1 year after
the injury). Non-traumatic SCI injuries can be included, given they are
neurologically stable conditions for 12 months (e.g. tumor, transverse
myelitis, but NOT Guilliane-Barré)
2. NLI C1- approximately T10 (inclusive, for upper motor neuron injuries
only), as determined by the International Standards for Neurological
Classiﬁcation of SCI (ISNCSCI)
3. Sufﬁcient diaphragmatic strength such that respiration is not
compromised with exercise.
4. Sufﬁcient upper extremity strength to use a front wheeled walker by
manual muscle testing (minimum triceps strength bilaterally of 3/5,
shoulder abduction and ﬂexion/extension 4/5)
5. AIS-C SCI & AIS-D SCI, as determined by the International Standards
for Neurological Classiﬁcation of SCI (ISNCSCI)
6. Ambulates at a self-selected speed of <0.44 m/s with or without
physical assistance and assistance device
7. Able to advance at least one leg forward (volitionally with lower
extremity movement (not as a result of trunk movement or spasticity)
while using parallel bars, walker or crutches, with or without braces, and
up to 2 people to assist with safety and balance only. Stepping is to be
performed by the patient (without PT assistance at the lower
extremities and no BWS).
8. 18–75 yrs, inclusive
9. No current or history of other neurological conditions
10. Screened and cleared by a physician
11. Involved in standing program or must be able to tolerate at least 15
min upright without signs or symptoms of orthostatic hypotension
12. Weigh 220 pounds (100 kg) or less
13. Be able to ﬁt into the Ekso device
14. Between approximately 5′0″ and 6′4″ (1.5 m and 1.9 m) tall
15. Standing hip width of approximately 18″ (45 cm) or less
16. Have near-normal range of motion in hips, knees, and ankles

1. AIS-A SCI or AIS-B SCI
2. Lower motor neuron injuries, as shown by absent reﬂexes during
bilateral quadriceps and Achilles tendon taps
3. < 3 months since previous intensive gait training regimen, FES cycling
program, and/or lower extremity Botox injections. The gait training
regimen was meant to be formal gait training with feedback for
progression of walking (i.e. PT sessions). Participant could have a regular
home exercise program and/or a walking exercise program with a
companion/ trainer for safety, but not for verbal or tactile cues or
feedback regarding gait in the 3 months before initiating the protocol. If
participant had a home exercise program and/or a walking exercise
program, these programs (except FES cycling) could be continued
without changes throughout the protocol. Electrical stimulation devices
used regularly for foot drop during ambulation could be considered a
brace and could continue to be used as usual throughout the protocol.
Upper extremity Botox injections were permissible before and during the
protocol. One or two PT sessions were allowed to obtain a new brace or
progress bracing and check for ﬁt and safety, but no sustained gait
training could occur.
4. Already walking at self-selected ambulation speeds of at least 0.44 m/s
with or without assistance
5. Currently involved in another intervention study
6. Concurrent neurological disease
7. Hip ﬂexion contracture greater than ~17°
8. Knee ﬂexion contracture greater than 12°
9. Unable to achieve neutral ankle dorsiﬂexion with passive stretch
(neutral with max 12° knee ﬂexion)
10. Leg length discrepancy
a. Greater than 0.5″ (1.27 cm) for upper leg b. Greater than 0.75″ (1.91 cm)
for lower leg
11. Spinal instability
12. Unresolved deep vein thrombosis
13. Uncontrolled autonomic dysreﬂexia
14. Severe muscular or skeletal pain
15. Spasticity that prevents joint motion (severe stiffness or rigidity,)
where both legs have a MAS score of 3 or higher for half or more of their
proximal lower extremity muscles; proximal muscles include hip ﬂexors/
extensors/adductors and knee ﬂexors/extensors.
16. Open skin ulcerations on buttocks or other body surfaces in contact
with exoskeleton or harness
17. Pregnancy
18. Cognitive impairments – unable to follow 2 steps commands and
communicate for pain or to stop session
19. Shoulder extension ROM < 50° excludes crutches during sit to stand
or vice versa. (Walking with crutches permitted.)
20. Participant requires the assistance of more than one therapist to
transfer safely.
21. Uncontrolled or severe orthostatic hypotension that limits standing
tolerance; deﬁned as sustained, symptomatic drops in systolic and
diastolic blood pressure when moving from sitting to standing
22. Active heterotrophic ossiﬁcation (HO), hip dysplasia, or hip/knee axis
abnormalities
23. Colostomy
24. History of long bone fractures since the SCI, secondary to
osteoporosis
25. Unable to sustain current medication regimen
26. Any reason the physician may deem as harmful to the participant to
enroll or continue in the study

Inherent to these assumptions was the assumption of a linear additive
model with equal sample sizes. However, since the sample size was below
30, this procedure could not be expected to give reliable probabilities and
a normal distribution could not be assumed. Therefore, a t distribution was
assumed [18].
A Student’s t test (paired sample) was used to compare the single group
pre- and post-test means (i.e., 10MWT, Berg Balance Scale, 6MWT, and
TUG). One-way analysis of variance techniques were used for multiple
comparisons (i.e., Treatment Groups). In addition, when it was found that
the variances were not homogeneous and the sampling distributions were
not normal, non-parametric alternatives were employed. Those included
the Wilcoxon–Mann–Whitney Rank Sum Test for two independent samples
Spinal Cord

[19] and the Wilcoxon test for analysis of variance, which is appropriate for
small sample sizes. Mean comparisons of repeated measures over time
were performed using Tukey–Kramer HSD with alpha = 0.05. Within-group
comparison refers to pre to post change for a single group, between-group
comparison refers to comparison of change between groups.
Binomial and polynomial outcomes (i.e., Velocity Cutoff and MCID)
were assessed using chi-square statistical tests of the hypothesis that the
response rates were the same in each sample category. Correction for
continuity, exact probabilities, and 95% conﬁdence intervals were
computed where appropriate. Univariate analysis with Fisher’s Exact
Test was employed to analyze dichotomous outcomes such as safety
endpoints.
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Fig. 1 Electromechanical devices used for the active intervention groups. A Photograph with permission, showing an SCI participant
training in the robotic exoskeleton suit. B Photograph with permission, showing an SCI participant from the Active Control group training
using the body weight supported treadmill prior to overground stepping practice.
All analyses were performed using JMP Statistical Software, Version 15.0
(SAS Institute Inc., Cary, NC).

RESULTS
Between September 26, 2016 and September 3, 2019, across
seven US sites (6 main study, 1 run-in), 45 participants were
enrolled, of which 33 were randomized to the main study and 12
enrolled as run-in participants (Fig. 2). Of the 33 randomized
participants, 25 completed the assessments and training related to
the primary endpoint analysis (per protocol); 9 Ekso, 10 Active
Control, 6 Passive Control. Withdrawals were not interventionrelated, and there were three SAEs described below. Baseline
clinical characteristics for the sample population in each group are
provided in Table 3. Clinical characteristics were statistically
comparable for all treatment groups at baseline.
Gait speed (primary)
Self-selected gait speed following the 12-week intervention
increased in the Ekso group by 51% (mean, SD; 0.18 ± 0.23 m/s)
Active Control by 32% (0.07 ± 0.11 m/s) and Passive Control 14%
(0.03 ± 0.03 m/s), within group and between group comparisons
p > 0.05 (Fig. 3, Table 4).
Maximal gait speed following the 12-week intervention
increased in the Ekso group by 44% (0.20 ± 0.24 m/s) Active
Control 50% (0.14 ± 0.18 m/s) and Passive Control 14% (0.03 ±
0.13 m/s) within group and between group comparisons p > 0.05.
The highest individual absolute speed improvement at both
self-selected and fast speeds was seen in the Ekso group. There
was a marginal effect of improving by repeated testing as seen in
the Passive Control group.
Mean improvement in walking speed for both intervention
groups at the follow-up visit were not statistically signiﬁcant
(p > 0.05).
Improvement above the MCID (0.15 m/s) [14] during the selfselected speed test was examined between groups, with the

highest responder proportion in the Ekso group at 3 of 9 or 1/3
of participants, 2 of 10 or 1/5 in the Active Control, and 0 in the
Passive Control group (between-group difference in proportions
p > 0.05).
For proportion of change in clinical ambulation category, the
highest proportion of responders was in the Ekso group at 5 of 9
participants, 3 of 10 of the Active Control improved ambulation
category, while 0 in the Passive Control group changed (betweengroup difference in proportions p < 0.05, Table 5).
Considering the midpoint assessment of the primary outcome
gait speed, categorical change (>0.44 m/s) we found that 4 of 5
(80%) responders in the Ekso group had achieved the threshold
change at the half-way point of the training regimen (after 6 of
12 weeks), 1 of 3 of the Active Control responders and 0 of 0 in
Passive Control.
Clinical endurance and functional balance assessment
The median distance covered in the 6MWT following the 12-week
intervention was 538.0 feet (Quartile 268.0–687.3) for the Ekso
Group, 346.6 feet (Quartile 219.5–711.5) for the Active Control, and
320.0 feet (Quartile 148.8–466.6) for the Passive Control representing improvements of 34%, 28%, and 18%, respectively. The
median time for TUG following intervention was 26.4 s (Quartile
17.3, 53.0), for the Ekso group, 30.0 s (Quartile 26.0, 70.7) Active
Control, and 46.0 s (Quartile 29.0, 64.9) for the Passive Control,
representing improvements of 18.7%, 19.9%, and 12.7% respectively. Within-group and between-group differences were not
signiﬁcant (p > 0.05) for both the 6MWT and TUG measures.
Use of assistive devices for independent walking
Change in assistive device used outside of the clinic compared to
baseline was assessed each training visit. The majority of
participants in both the Ekso group (8/9) and the Active Control
group (7/10) showed no change in type of assistive device used
throughout the duration of the protocol. Of those that did report a
change, one participant in the Ekso group changed from using
Spinal Cord
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(A) WISE trial Ekso training progression strategy. (B) WISE trial Active Control training progression strategy.

Trajectory controlled:
adaptive to ﬁxed
Trajectory free: 2Free

Trajectory controlled:
adaptive to ﬁxed
Trajectory free: 2Free

Bilateral

Bilateral

Bilateral

Anytime session 3+

Training guidelines

Progression
guidelines

Trajectory controlled: adaptive

Trajectory controlled: adaptive

Bilateral

Sessions 1–3

Swing assist

Assist

Timeline and
settings

(11) Step monitors are to be used during any OG gait training.

Balance and gait progression
Consistently hitting >300 steps per session
Adjust targets/swing time/step length as appropriate

Considerations

Step count must be at least 300 within trajectory.
Must include 5 min warm-up at beginning and 2 min
cool down at end in bilateral adaptive.
Borg range 12-17 to prevent fatigue early in the session
No more than 3 swing completes per minute in Fixed
assist.
(If so, then increase Fixed swing assist by 10 or reduce
swing complete time)
No unilateral trajectory-free stepping to avoid
promoting gait asymmetries.

Step count must be at least 300 within trajectory.
Must include 5 min warm-up at beginning and 2 min
cool down at end in bilateral adaptive.
Borg range 12-17 to prevent fatigue early in the session
No more than 3 swing completes per minute in
Fixed assist
(If so, then increase Fixed swing assist by 10 or reduce
swing complete time)
No unilateral trajectory-free stepping to avoid
promoting gait asymmetries.

PT may progress the participant by lowering the ﬁxed assist for each
leg, as tolerated and clinically appropriate.
Stance support may be changed from “Full” to “Flex”.
Once initial 300 steps in trajectory are completed, PT may progress the
participant via trajectory-free stepping using “2Free”.
Stance support should begin at appropriate level. As participant
improves stance control, support may be reduced as tolerated and
clinically appropriate.
Swing support should be assessed at “neutral”. If a leg is not able to
complete a step, “high”/”low assistance” may be provided for more
normalized stepping. If a leg is stepping far outside of the general
trajectory, “high”/”low resistance” may be provided for more normalized
stepping. Progress to more symmetrical gait.
If initial 300 steps within trajectory is achieved/projected, the therapist
may challenge the participant by the following, as tolerated and
clinically appropriate:
Lower the Fixed assist bilaterally as appropriate
Stance support may be changed from “Full” to “Flex”.
Once initial 300 steps in trajectory are completed, set swing support at
appropriate assistance/resistance for an appropriate clinical challenge

Pre-gait weight shifting when needed.
Adjust targets/swing time/step length as appropriate
Once participant has consistently managed >300 steps/session,
Step count with crutches should be at least 80% of step
progress to crutches if appropriate and encourage minimal UE loading count with walker.

Pre-gait weight shifting
Stance support remains at “Full”
Minimize upper extremity loading. Optimize step height; swing time;
step length; targets; etc.

Progression and adjustments

(10) If participant is performing overground gait training, session will consist of 30 min of gait training in the Ekso, followed by 15 min performing overground gait training for a total of 45 min.

(9) If participant is not yet performing overground gait training, all 45 min of session will be done in Ekso.

(8) Overground walking will be included when the participant requires only minimal assistance of one therapist and the assistance of one aide to control the assistive device for at least 10 m.

(7) Excluding Ekso donning and dofﬁng time, each session will last a total of 45 min, which will include standing/up time, walking time, and seated rest breaks.

(6) If the participant is exceeding 750 steps per session, the therapist should increase the challenge to the participant.

(5) Each leg may be considered individually when considering reducing Fixed assist level, or choosing high/low assistance/resistance in 2Free. No unilateral trajectory-free stepping is allowed to
avoid promoting gait asymmetries.

(4) All exoskeleton and assistive device progressions should be done in Bilateral/Adaptive. (Examples: FRW to Crutches; step length increase; step height decrease; target adjustment; turning mode or
technique).

(3) All sessions after session #3 must include a 5-min warm-up and end with a 2-min cool down in Bilateral/Adaptive.

(2) Sessions begin with a goal of a minimum of 300 steps per session in Ekso within trajectory. Then can do outside of trajectory.

(1) Sessions are divided into three 15-min segments. This includes any rest breaks required, as well as a 5-min warm-up and 2-min cool down per session required by week 2.

General rules for Ekso Active Group:

(A)

Table 2.
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continued

Engage hip control and motor control (concentric/
eccentric) of stepping, arm-swing
Ensure good posture, stepping kinematics, and joint
protection.
Borg range 12–17 to prevent fatigue early in the session
Engage motor control of posture, hips, symmetric
stepping, arm swing (when evaluable)
Ensure good posture, stepping kinematics, and joint
protection.
Borg range 12–17 to prevent fatigue early in the session

• Decrease BWS if tolerated
• Increase/decrease speed
• Increase bout lengths

• Decrease BWS if tolerated
• Increase/decrease speed
• Decrease physical assistance
• Increase bout lengths, decrease rest breaks
• Introduce walking sideways, backwards, stepping over obstacles,
quick speed changes, quick start/stops if tolerated
• Decrease BWS if tolerated
• Increase/decrease speed
• Decrease physical assistance
• Increase bout lengths, decrease rest breaks
• Continue or introduce walking sideways, backwards, stepping over
obstacles, quick speed changes, quick start/stops

• Posture
• Good stepping kinematics
• Increase load as toleratedb
• Increase range of speeds as tolerated
All sessions should have 5-min warm-up and
2-min cool down.

• Increase load weekly if toleratedb
• Increase range of speeds as tolerated
• Increase independence
• Increase endurance
All sessions should have 5-min warm-up and
2-min cool down.

• Increase load weekly if toleratedb
• Increase range of speeds by as tolerated
• Increase independence
• Increase endurance
• Increase adaptability
All sessions should have ~5-min warm-up
and ~2-min cool down.

Sessions 4–6

Sessions 7–18

Sessions 19–36

BWS body weight support, BWSTT Body Weight Supported Treadmill Training, OG overground.
a
PT can adjust one or multiple parameters at a time. PT can adjust parameters for interval training, e.g. lower BWS for 5 min.
b
Training intensity should be increased ﬁrst by increasing loading. If amount of loading puts participant or trainers at risk for injury, then increasing range of speeds or independence can be the focus of
increasing intensity.

Engage posture and both swing/stance phases of
stepping
Ensure good posture, stepping kinematics, and joint
protection.
Borg range 12–17 to prevent fatigue early in the session

Determine comfortable BWS, stepping range of speeds, amount of
physical assistance at each location, and bout length

• Determine parameters for best kinematics
• Participant familiarization
• Posture

Sessions 1–3

Considerations
Educate and engage posture and basic stepping
Educate and ensure joint protection

Progression and adjustments as tolerateda

Focus

(7) Step monitors are to be used during the full 45 min= of gait training.

b. If the initial 300 steps are completed by the end of the ﬁrst segment, the middle 15-min segment can be continued gait training in BWSTT or OG gait training, per PT choice. The ﬁnal 15-min
segment must be OG gait training.

a. If the initial 300 steps are not completed by the end of the ﬁrst segment, the middle 15-min segment must be gait training in BWSTT, and the ﬁnal 15-min segment must be OG gait training.

(6) Once the OG criterion is achieved:

(5) Participants will perform gait training with BWSTT for the full session (all 3 segments) until the OG criterion is met. Participants may proceed to overground gait training without BWS only when
they require minimal physical assistance of the physical therapist, plus assistive device control or supervision of another team member for at least 10 m.

(4) BWS and speed are to be determined by the physical therapist based on appropriate stepping kinematics, level of challenge to the participant, and safety of the participant and trainer(s).

(3) Manual assistance from the physical therapy team to facilitate normal stepping kinematics is permissible.

(2) Participants will perform gait training with BWSTT for the full session (all 3 segments) until the OG criterion is met. This gait training must continue for a minimum of 300 steps at the beginning of
each session.

(1) Sessions are divided into three 15-min segments. This includes any rest breaks required, as well as a 5-min warm-up and 2-min cool down per session required by week 2.

General rules for Active Controls:

(B)

Table 2.
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SCI screened for eligibility
(n= 117)
Screen failed (n=72)
Qualiﬁed for study inclusion
(n= 45)
Enrolled as Run-in study
parcipants (n=12)
Randomized (n=33)
Allocated to Ekso (n=14)

Allocated to Acve Control (n= 13)

- Excluded (n=1)
- Withdrew (n=1)
- Outcome assessment
incomplete (n=1)

- Withdrew (n=2)
- Outcome assessment
incomplete (n=3)

PRIMARY END POINT

PRIMARY END POINT

PRIMARY END POINT

Included in post-intervenon
analysis, per protocol (n=9)

Included in post-intervenon
analysis, per protocol (n=10)

Included in post-intervenon
analysis, per protocol (n=6)

Included in the follow-up
analysis (n=9)

Fig. 2

Allocated to Passive Control (n= 6)

Included in the follow-up
analysis (n=10)

Study consort diagram.

1 crutch to 2 crutches between midpoint and endpoint
evaluations. Three participants in the Active Control group
progressed to a less restrictive assistive device between baseline
and midpoint assessments with one participant regressing back to
their baseline device between midpoint and endpoint. No
changes in type of assistive device used were observed in the
Passive Control group throughout the duration of the study.
Tolerance and safety
Three SAEs occurred during the trial: two were urinary tract
infections (UTI) unrelated to the device, and one participant in the
active group was admitted to a hospital with lower extremity
numbness and a UTI. The numbness was deemed by the DSMB to
be “possibly related” to the Active BWSTT group. No falls occurred
during training or evaluation sessions in any group. From the total
sample of 45 participants (run-in plus main study participants),
adverse events that were deemed “possibly” or “probably” related
to the device or training include the following: 12 (8 Ekso, 4 Active)
upper and lower extremity musculoskeletal issues, including
orthopedic pain; 4 (3 Ekso, 1 Active) neurological issues, including
increased spasticity; 6 (5 Ekso, 1 Active) skin issues; and 1 (Ekso)
visceral issue. Three of these were considered severe: 2 musculoskeletal (1 Ekso, 1 Active) and 1 neurological (Ekso). Ten of these AEs
were deemed “unanticipated” possibly related to Ekso training (8) or
BWSTT (2). In summary, active training was generally well tolerated,
with several mixed AE reported in both groups.
Therapist workload
Results from the TLX scores showed statistically signiﬁcant
differences in favor of BWS training in the Frustration domain
(p = 0.021), while all other domains were comparable (Mental,
Physical, Temporal, Effort, Performance; p > 0.05).
DISCUSSION
The present randomized, controlled, multi-site clinical trial assessing intensive training using OG exoskeleton robotics (1) conﬁrmed
safe and feasible implementation in an outpatient setting, (2)
found group mean increase in independent gait speed was not
statistically signiﬁcant, and (3) demonstrated clinically signiﬁcant
Spinal Cord

improvement for transition in gait speed category from home to
community ambulation.
Robotic exoskeleton-based gait training is reported to have a
beneﬁcial effect on cardiovascular health in individuals with SCI [20],
a potential improvement of bone health [21], and psychological
beneﬁt [22]. Evidence is controversial for training-related improvement on independent gait function as measured by walking speed
[23, 24]. Our study rationale was that (a) participants with motor
weakness who can physically engage in a high-dose training
program, might reasonably be expected to beneﬁt, and (b)
exoskeleton robotic technologies are a practical solution to facilitate
high-repetition OG gait training, and could potentially replace the
manual labor component traditionally provided by therapists with
inherent occupational risks.
The current study builds on existing literature that supports the
safety and feasibility of intensive exoskeleton robotic training in
SCI [10, 25, 26], and our results showed a statistically signiﬁcant
beneﬁt for improved gait speed category associated with Ekso
training. The proportion of responders above the MCID was not
statistically signiﬁcant, however, the Ekso group had the highest
percentage of responders. We note that the MCID was conservatively set pre-trial at 0.15 m/s, however, the MCID in a population
with iSCI may be considered less than half this value (0.06 m/s
[27]), and our ﬁndings should be interpreted in this context.
Modest improvement in functional balance (TUG) was not
signiﬁcant in either the Ekso or Active Control group.
Given the ﬁnancial limitations of the sponsor, we recognize
that this study was underpowered to prove signiﬁcant effects
and have calculated sample size required for a future trial based
on our data. Assuming normally distributed data, a sample size
of 9 in the Ekso group and 6 in the Passive Control will have 24%
power to detect a difference in absolute change from baseline
to endpoint evaluation for mean self-selected 10MWT between
the Ekso group and the Passive Control of 0.15 m/s (the
difference between the Ekso Group mean, μ1, of 0.18 m/s and
the Passive Control mean, μ2, of 0.03 m/s) assuming that the
common standard deviation is 0.21 m/s using a two group t-test
with a 0.05 two-sided signiﬁcance level. Moreover, a sample size
of 32 in each group would be needed to have 80% power to
detect a difference in group means of 0.15 m/s. In addition,
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7
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36

46

40
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50
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32
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38
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UEMS

1-1

1-1

0-0

0-0

0-1

1-0

0-0

2–2

0-0

0-0

1-1

1-1

1-1

0-0

1-1

0-0

0-0

0-0

2-2

1-1

1-1

1-0

1-1

1-1

1-1

1-1

2-2

0-2

0-0

2-2

SCATS
(clonus) (L-R)

0.17
0.34
013
0.33
0.12
0.24

−0.56
−0.09
−0.12
−0.23

0.35

−0.44

−0.94

0.03

−1.12

−0.14

0.17
0.48

0.16

−2.47
−0.22

0.26

−0.41
−0.09

0.16
0.30

0.35

−0.31
−0.12

0.09

−2.63
−0.26

0.24
0.30

–
−0.49

0.09
−1.60

−0.29

0.42
−0.35

−0.50

−0.53

0.38
0.16

−0.29

0.34

0.43

−0.63

0.26

0.22

−1.20

0.00

0.41

−1.00

−1.42

0.18
0.34

0.00

Gait
speed
(SS, m/s)

−0.11

SCI-SET
Total Score

Baseline clinical and demographic data for all enrolled participants in (A) Ekso, (B) Active Control and (C) Passive Control groups. Baseline characteristics were comparable across all treatment groups.
AIS ASIA Impairment Scale, ASIA (American Spinal Injury Association), ISNCSCI International Standard for Neurological Classiﬁcation of Spinal Cord Injury, WISCI-II Walking Index for Spinal Cord Injury, SCI-FAI Spinal
Cord Injury Functional Ambulation Index, SCIM-III Spinal Cord Independence Measure, LEMS Lower Extremity Motor Score, UEMS Upper Extremity Motor Score, SCATS Spinal Cord Assessment Tool for Spastic
Reﬂexes, SCI-SET Spinal Cord Injury Spasticity Evaluation Tool, SS self-selected.
a
Per Protocol Group.
b
Responder to > 0.44 m/s threshold.
c
Responder to MCID threshold.
d
Responder to both thresholds.

M

01-116a

(C)

35

M

26

F

41

Age (yrs)

02-108a,b

Gender

01-123a

(A)

Subject ID

Control group baseline clinical characteristics.

Table 3. Baseline clinical and demographic data for all enrolled participants: (A) Ekso group baseline clinical characteristics, (B) Active Control group baseline clinical characteristics, and (C) Passive
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Use of assistive devices for independent walking
The typical outcome measure in rehabilitation for recovery of
gait is gait speed (10MWT), often without regard to the assistive
device used [28]. Data are compared using the same device pre
to post training. However, a change to a less supportive assistive
device over the course of a study protocol may itself indicate an
improvement in function and may be related to gait speed,
balance, independence, and/or quality of life. In this study, the
10MWT was performed with both baseline and progression of
assistive devices over time (i.e. less dependence), as tolerated by
the participants. Few participants reported a change in reliance
on assistive devices during the protocol timeframe with the
majority of participants showing no change. Varied factors may
also be related to the decision to progress with respect to type
of assistive device, independent of gait function. While our study
showed little improvement regarding less dependence on
assistive devices, we recognize that this could be an important
outcome to measure in future studies. However, progression of
assistive devices should follow strict a priori criteria, and interrater reliability of this progression should be demonstrated by
the assessors.

when the sample size in each group is 32, a two group 0.025
one-sided t-test will have 81% power to reject the null
hypothesis that the Ekso Group and the Passive Control are
not equivalent, in favor of the alternative hypothesis that the
means of the two groups are equivalent, assuming that the
expected difference in means is 0.15 m/s and the common
standard deviation is 0.21 m/s.
The proposed 32 participants in each study arm are consistent
with recommendations in the literature, suggesting that an RCT
with as few as 25 homogeneous subjects (per study arm) with a
suitable Active Control may be sufﬁcient to detect beneﬁt of
robot-assisted training [24]. With the variance of response in the
active groups, we propose that an efﬁcacy trial of this nature may
be less dependent on sample size, and more on participant
selection for the outcome of independent gait speed. In our
sample, we aimed for participant homogeneity in a zone of
enough function that one could anticipate a training-related
improvement, but not so functional that robotic training would
not be warranted. This criterion was insufﬁcient to prove an
average effect across the group given our small sample size, and
other baseline predictive factors should be established, such that
meaningful entry criteria for participants in future trials yields a
more consistent treatment response.

NASA-Task Load Index (TLX)
Task load was perceived to be similar for both therapist groups,
except frustration which was signiﬁcantly higher in the therapists
working with the Ekso group. Scores in both groups were low,
however, and the magnitude of the mean difference was small.
Neither technology is likely to be frustrating when used by
experienced clinicians [29].
All of the NASA-TLX dimensions, in both groups, except effort,
were rated as low. These technologies may therefore result in
reduced therapist workloads. Physical therapists have reported
high rates of work-related pain, in part because of job tasks that
require lifting and guarding patients but therapists in the current
sample reported low physical demands associated with ambulation training [5, 6, 30, 31]. It should be noted, however, that only
participants who could advance at least one lower extremity were
included. In the case of BWSTT, advancing the lower extremities
manually can result in high physical loads for therapists and
increased injury frequency and severity.
The effort was the only dimension that was rated as high, where
effort is a combination of mental and physical demands (both
rated as low). Additional studies should seek to identify the

Fig. 3 Change in gait speed post intervention relative to preintervention: Graphical representation of absolute change in gait
speed (m/sec; meters/second).

Table 4.

Change in gait speed post intervention relative to pre-intervention: Statistics for absolute change in gait speed in m/s.

Quantiles
Level

Median

75%

90%

0.01

0.01

0.02

0.10

0.33

0.69

0.69

Group 2: Active Control

−0.09

−0.08

−0.02

0.07

0.15

0.26

0.27

Group 3: Passive Control
Means and Std Deviations

−0.01

−0.01

0.01

0.03

0.06

0.07

0.07

Group 1: Ekso Intervention

Minimum

10%

25%

Lower 95%

Maximum

Level

Number

Mean

Std Dev

Std Err Mean

Group 1: Ekso Intervention

9

0.18

0.23

0.08

0.00

Upper 95%
0.36

Group 2: Active Control

10

0.07

0.11

0.03

−0.00

0.15

Group 3: Passive Control

6

0.03

0.03

0.01

−0.00

0.06

Means Comparisons for all pairs (Tukey-Kramer HSD)
Level

- Level

Difference

Std Err Dif

Lower CL

Upper CL

p-Value

Group 1: Ekso Intervention

Group 3: Passive Control

0.15

0.08

−0.06

0.36

0.181

Group 1: Ekso Intervention

Group 2: Active Control

0.11

0.07

−0.07

0.29

0.309

Group 2: Active Control

Group 3: Passive Control

0.04

0.08

−0.16

0.24

0.854
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Table 5.

Change in clinical gait speed category.

Self-selected speed averaged trials 1 and 2 (Per Protocol Population)
Velocity for home v community
Evaluation/Group

n

Median (IQR)

MCID (Δ from baseline)

P < 0.44 m/s

P > 0.44 m/s

P < 0.15 m/s

P > 0.15 m/s

Baseline
EKSO Group

10

0.30 (0.16–0.39)

100%

0%

Active Control

11

0.24 (0.14–0.30)

100%

0%

Passive Control

6

0.22 (0.13–0.33)

100%

0%

Endpoint
EKSO Group

9

0.46 (0.22–0.65)

44.4%

55.6%

66.7%

33.3%

Active Control

10

0.29 (0.16–0.46)

70.0%

30.0%

80.0%

20.0%

Passive Control

6

0.25 (0.15–0.35)

100.0%

0.0%

100.0%

0.0%

Change in gait speed (self-selected) category after the 12-week intervention relative to baseline for patients completing the protocol as assigned (home vs
community ambulation speed threshold, and Minimal Clinically Important Difference, MCID). As per the inclusion criteria, at baseline, all participants were at or
below home ambulation gait speed. Post intervention, the Ekso group had the highest proportion of participants that moved into the community ambulation
category (statistically signiﬁcant), while Passive Control group had zero change. One third of patients (3 of 9) in the Ekso group exceeded the MCID, the highest
of the three groups, 2 of 10 of the Active Control, and 0 of 6 in the Passive Control group exceeded the MCID.
IQR Inter Quartile Range.

patient and therapist factors that can inﬂuence the ratings on the
NASA TLX.
Considerations for clinical efﬁcacy of robot-assisted gait
therapy in iSCI
Foremost in consideration of treatment efﬁcacy would be
participant suitability, robot type, operation, and overall training
regimen. Treatment speciﬁcation is important to apply to robotic
therapies as other interventions in rehabilitation medicine, where
active ingredients are matched with treatment targets [32]. The
overall dose is also a known inﬂuential covariate in behavioral
neurorehabilitation trials. The present study showed some indication of the rate of improvement after 6 weeks (Ekso), which
suggests that the overall dose should be examined systematically.
As well, the long-term after-effects might be differentially affected
by duration of training.
We also considered the outcome to be assessed in determining
treatment efﬁcacy, where the outcome may be matched to training
speciﬁcity. Here we selected gait speed (independent and outside of
the device), which is considered a gold standard in gait rehabilitation, however, some argue [33] that important treatment-related
clinical improvement can be measured in other domains without
change in gait speed.
Finally, how the outcome change is statistically determined, at
the group or individual level is important to interpret the
ﬁndings and draw conclusions. The gold standard in clinical
trials is to show superiority or non-inferiority of a novel
intervention group versus existing best practice. Robust effects
should be demonstrated at the group level, even accounting for
intragroup variability, by enrolling a sufﬁcient sample for
statistical power. However, a recent study sheds light on this
approach, indicating the lack of group-to-individual generalizability [34]. The next step is to reﬁne what constitutes who
might ‘reasonably respond’, and systematically test it. Identifying features of who does not respond is equally important as to
who does, so the non-responders can consider alternative
interventions that improve function in other domains and
ultimately quality of life.
Limitations and recommendations for future studies
The simple randomization method in the present study resulted
in non-signiﬁcant statistical difference in baseline features
between the three groups, however, trends in differences may
be considered in the clinical interpretation of our ﬁndings. Future

clinical trials should also consider (1) sufﬁcient sample size to
detect a statistical difference in group mean data, (2) anticipating
a small increase in gait speed in the Passive Control group
potentially a repeated assessment on the 10MWT or association
with a gait clinical trial, (3) participant characteristics (clinical
features) that might limit the response to this form of training, (4)
restricting the number of assessments on a given day to avoid
testing fatigue, and (5) including patient-reported outcome
measures that detect potentially small outcome differences in
domains not easily measured by the usually applied clinical
assessments.
CONCLUSIONS
We conclude that an intensive three-month course of exoskeleton
robotic training in people with iSCI and limited independent gait
function, can improve clinical ambulation category in a portion of
participants. Further exploration of individual characteristics that
predict individual-level response to intervention is needed, and
may be useful for future trial inclusion criteria, as well as clinical
prescription.
DATA AVAILABILITY
Due to the nature of this research, participants of this study did not agree for their
data to be shared publicly, so supporting data is not available.
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